Grail’s Galleri blood test sees 33% stock jump as FDA hints at favorable advisory panel outlook

Shares of Grail rose sharply on Monday after the FDA released documents ahead of an advisory committee meeting, suggesting a positive view of the company’s multi‑cancer blood test, Galleri.

The upcoming panel, scheduled for Wednesday, will review data on the test’s ability to detect cancers early. While FDA approval is not guaranteed, a favorable recommendation could pave the way for Medicare and private‑insurance reimbursement, expanding the test’s market reach.

Investors had already been positioning for the meeting, and the stock’s surge reflects optimism that regulatory clearance could boost the company’s commercial prospects, even though the agency is not obligated to follow the advisory panel’s advice.